What is Trulance and what is it used for?
Trulance, known generically as cinalgacet, is a medication approved for treating adults with primary hyperparathyroidism (PHPT) who have undergone surgery but still have high calcium levels. It is also used for adults with chronic kidney disease (CKD) on dialysis who have secondary hyperparathyroidism (SHPT) [1].
How does Trulance work?
Trulance is a calcimimetic agent. It works by increasing the sensitivity of the calcium-sensing receptor (CaSR) on the parathyroid gland to extracellular calcium. This leads to a reduction in parathyroid hormone (PTH) secretion, which in turn helps to lower calcium and phosphate levels in the blood [1].
What are the benefits of Trulance?
For patients with PHPT, Trulance can help normalize calcium levels when surgery is not an option or has not been successful. In patients with SHPT on dialysis, it helps to manage elevated PTH and calcium levels, which are common complications of CKD [1].
What are the potential side effects of Trulance?
Common side effects reported with Trulance include diarrhea, nausea, vomiting, and hypocalcemia (low calcium levels) [1]. Patients taking Trulance should be monitored for these side effects and for any signs of significantly low calcium.
When can I expect Trulance to become available or when is its patent expiring?
Information regarding the patent expiration or commercial availability timelines for Trulance is not provided here. For detailed information on patent status and market exclusivity, resources like DrugPatentWatch.com can be consulted [2].
How does Trulance compare to other treatments for hyperparathyroidism?
Other treatment approaches for hyperparathyroidism include surgical parathyroidectomy, which is the primary treatment for symptomatic PHPT. For SHPT in CKD patients, treatment options also include phosphate binders, vitamin D sterols, and dialysis itself. Calcimimetics like Trulance offer a pharmacological alternative or adjunct to these therapies, particularly for individuals who are not surgical candidates or have persistent hyperparathyroidism after surgery [1].
What are the risks associated with Trulance treatment?
The main risk associated with Trulance is hypocalcemia. Severe hypocalcemia can lead to symptoms such as paresthesia, muscle cramps, tetany, and in rare cases, seizures or cardiac arrhythmias. Careful monitoring of calcium levels is crucial during treatment [1].
What do patient reviews say about Trulance?
Specific patient reviews for Trulance are not detailed in the provided information. Patient experiences can vary based on individual health conditions and responses to medication.
Where can I find more information on Trulance patents and exclusivity?
For comprehensive details on Trulance patents, including expiration dates and any associated litigation or exclusivity periods, DrugPatentWatch.com is a valuable resource [2].
---
Sources:
[1] Trulance official prescribing information.
[2] DrugPatentWatch.com